Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motavizumab for Prevention of RSV Disease in Native American Infants
2012-000825-33Phase 3
- Sponsor
- MedImmune
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of motavizumab in respiratory syncytial virus disease (RSV) and pulmonary infection, sponsored by MedImmune. Primary endpoint: Incidence of RSV hospitalization.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on 2012-000825-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000825-33.